SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cambridge Antibody Technology Group
An SI Board Since December 1999
Posts SubjectMarks Bans
625 23 0
Emcee:  Jongmans Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
600congratulations if you still own some. i left awhile agoMadharry-5/15/2006
599MEDX n PDLI are the big players left in the game now...dr.praveen-5/14/2006
598This is getting irritating.nigel bates-5/14/2006
597UPDATE 1-AstraZeneca in talks to buy UK biotech firm CAT Sun May 14, 2006 9:22 Ascaram(o)uche-5/14/2006
596Just took another look at CATG. Think I'll wait longer. JnJ/medx progress keokalani'nui-4/19/2006
595From ABT report: Sales of the rheumatoid arthritis medication Humira, the compasjemmeri-4/19/2006
594From Iceberg, results of cnto's anti il-12/23 Mab in psoriasis. Message 223keokalani'nui-3/30/2006
593Cambridge Antibody Drug Now Blockbuster <i>[Headlines like this I like. AsA.J. Mullen-1/25/2006
592<pre>The following is a summary of Abbott's fourth-quarter 2005 sales nigel bates-1/25/2006
591<i>From Monday's results statement...</i> Product Development Pnigel bates-11/29/2005
590Cambridge Antibody Technology Acquires Oncology Product Candidates from Genencorsjemmeri-11/1/2005
589>>Or maybe the .4% was the cost of administering the subroyalties :-) Wimptuck-10/26/2005
588Works out as their experts calling it an 87% chance of winning. Seems reasonablerkrw-10/26/2005
587How about reasonable wimps? As investors our interest differs somewhat from manA.J. Mullen-10/26/2005
586If the 3.1 % best case scenario is accurate, I think it's reasonable. At cursjemmeri-10/26/2005
585CAT today settled with Abbott for 2.688% (net of everything), ongoing. Reasonanigel bates-10/26/2005
584Possibly; a decent lupus treatment would have been worth a lot. ( Don't fornigel bates-10/6/2005
583Widening the approval for arthritis seems important to me, yet the stock barely A.J. Mullen-10/5/2005
582CATG & Merck find an aB that binds to the same target as Fuzeon: >>Putuck-10/4/2005
581UPDATE 1-Abbott says FDA OKs new uses of Humira CHICAGO, Oct 4 (Reuters) - Abbonigel bates-10/4/2005
580Humira Q2.... <pre>The following is a summary of Abbott's second-quarnigel bates-7/13/2005
579GSK exercises option on LymphoStat-B: Message 21482303nigel bates-7/7/2005
578Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion for Treatment of Pnigel bates-6/27/2005
577Abbott Receives Positive Opinion for HUMIRA(R) (Adalimumab) as First-Line Treatmnigel bates-6/27/2005
576CAMBRIDGE ANTIBODY TECHNOLOGY ANNOUNCES DATA FROM PHASE I CLINICAL TRIAL OF CAT-nigel bates-6/23/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News